Enveric Biosciences (NASDAQ:ENVB) Stock Price Down 7.4% – Should You Sell?

Shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) were down 7.4% on Thursday . The stock traded as low as $2.59 and last traded at $2.63. Approximately 46,434 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 61,692 shares. The stock had previously closed at $2.84.

Analysts Set New Price Targets

ENVB has been the subject of a number of analyst reports. Wall Street Zen raised Enveric Biosciences to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $120.00.

Enveric Biosciences Trading Down 9.9%

The firm’s fifty day moving average price is $4.48 and its 200-day moving average price is $8.07. The company has a market cap of $1.42 million, a price-to-earnings ratio of -0.06 and a beta of 0.30.

Enveric Biosciences (NASDAQ:ENVB) last posted its earnings results on Friday, November 14th. The company reported ($10.81) earnings per share for the quarter, topping the consensus estimate of ($63.00) by $52.19. As a group, research analysts anticipate that Enveric Biosciences, Inc. will post -31.18 EPS for the current year.

Hedge Funds Weigh In On Enveric Biosciences

A hedge fund recently raised its stake in Enveric Biosciences stock. AdvisorShares Investments LLC increased its stake in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) by 14.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 103,679 shares of the company’s stock after buying an additional 13,355 shares during the period. AdvisorShares Investments LLC owned 4.20% of Enveric Biosciences worth $125,000 as of its most recent filing with the SEC. 13.82% of the stock is owned by institutional investors and hedge funds.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.